 In hepatic cells this transcription factor seems to increase the expression of PEPCK and glycogen-6-phosphatase (the same enzymes that are blocked via the metformin/AMPK/SHP pathway).Blocking this transcription factor offers an opportunity for novel therapies for diabetes mellitus.In pancreatic alpha-cells FOXO1 is important in regulating prepro-glucagon expression.